Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Vanda ( (VNDA) ) has shared an update.
On December 4, 2025, Vanda Pharmaceuticals announced that the FDA has lifted the partial clinical hold on their drug tradipitant, intended for treating motion sickness. This decision, following a formal dispute resolution and expedited review, allows Vanda to extend clinical studies of tradipitant, potentially positioning it as the first new pharmacologic treatment for motion sickness in over 40 years, with a pending New Drug Application review set for completion by December 30, 2025.
The most recent analyst rating on (VNDA) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Vanda stock, see the VNDA Stock Forecast page.
Spark’s Take on VNDA Stock
According to Spark, TipRanks’ AI Analyst, VNDA is a Neutral.
Vanda Pharmaceuticals’ overall stock score reflects significant financial challenges, weak technical indicators, and unattractive valuation. Despite potential growth from new products and corporate events, operational inefficiencies and regulatory challenges weigh heavily on the stock.
To see Spark’s full report on VNDA stock, click here.
More about Vanda
Vanda Pharmaceuticals Inc. is a global biopharmaceutical company focused on developing and commercializing innovative therapies to address high unmet medical needs, aiming to improve patients’ lives.
Average Trading Volume: 668,007
Technical Sentiment Signal: Buy
Current Market Cap: $290.8M
See more insights into VNDA stock on TipRanks’ Stock Analysis page.